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The Open Artery Hypothesis Charles B. Kim, MD; Eugene Braunwald, MD T he salvage of severely ischemic myocardium by means of thrombolytic therapy represents a major advance in the management of acute myocardial infarction (AMI). Reperfusion was initially studied in canine models of evolving infarction with the temporary mechanical occlusion of a coronary artery and its subsequent release.1-3 As shown by Reimer et a14 and Reimer and Jennings,5 such occlusion is followed by a wave front of myocardial necrosis spreading from endocardium to epicardium, with an inverse relation between the time to reperfusion and the ultimate size and extent of transmurality of the infarct. They and Kloner et a16 demonstrated in the dog that a rim of subepicardial myocardium could be salvaged when reperfusion occurred within 6 hours of coronary occlusion. In 1980, DeWood et a17 identified thrombotic occlusion of an epicardial coronary artery as the usual proximate cause of AMI in patients. Shortly thereafter, thrombolytic agents and other measures to restore reperfusion were developed to treat patients with this condition (see Reference 8 for review of early studies).
Subsequently, numerous placebo-controlled trials in patients with AMI confirmed the beneficial effects of thrombolytic therapy.9-14 When tissue-type plasminogen activator (t-PA), streptokinase (SK), and anisoylated plasminogen-streptokinase activator complex (APSAC) were administered during the early phases of AMI, mortality was reduced significantly. Early in the thrombolytic era, it became clear that, as had been observed in the case of myocardial salvage in the canine model, benefit was greatest when such therapy was initiated within 1 hour of symptom onset. 8, 10, 13, 15 As originally conceived, thrombolytic therapy was intended to interrupt the progression from myocardial ischemia to necrosis that resulted from occlusion of the infarct-related artery (IRA) (Fig 1) [19] [20] [21] This modest improvement in LVEF induced by reperfusion is due to the preservation of regional myocardial function in the distribution of the IRA. 21 Like patient survival, the extent to which thrombolysis preserves left ventricular function depends on the time interval between the onset of symptoms and commencement of treatment. [19] [20] [21] [22] [23] [24] [25] The sequence described above, ie, early reperfusion of an occluded IRA -* myocardial salvage --preservation of regional function --preservation of global left ventricular function -> improved patient survival, is supported by many experimental and clinical studies and has become so widely accepted that it could be called a "paradigm." A key aspect of this paradigm is that the time of opening of the IRA is of central importance to the benefit achieved. Stated in another way, the effects of reestablishing an open artery may be considered to be "time dependent."
Challenges to the Paradigm However, several findings have recently come to light that are not consistent with this paradigm, raising questions about whether the benefits of reperfusion are entirely (or even in large measure) secondary to myocardial salvage. These observations suggest that late reperfusion of an occluded coronary artery, ie, that achieved after the period of time generally considered necessary to achieve myocardial salvage, favorably affects clinical outcome.26-29 These effects may be considered to be the "time-independent" effects of an open IRA.
The purpose of this article is (1) to review these observations, (2) relation between LVEF and survival noted in the prethrombolytic era compared with the thrombolytic era. In studies carried out before the advent of reperfusion therapy, the LVEF before hospital discharge was inversely related to subsequent mortality.37 If, as would be dictated by the paradigm, the benefit of thrombolysis was attributable to the improvement in left ventricular function, the relation between LVEF and survival should not be altered by thrombolytic therapy (although both ventricular function and survival would be expected to be more favorable in patients so treated). However, in the TIMI-II trial, in which all patients received thrombolytic therapy, often followed by mechanical revascularization, 1-year mortality was surprisingly low (5.3%) in those with a predischarge LVEF below 40%,38 whereas in the prethrombolytic era, the 1-year mortality among patients with similar ejection fractions exceeded 15% to 20%. Thus, at any level of LVEF, survival after thrombolytic therapy appears to be greater than that reported during the prethrombolytic era. Thrombolytic therapy thus appears to confer a greater survival benefit than can be accounted for by the improvement in left ventricular function.
Beneficial Effects of Late Reperfusion
Another major challenge to the paradigm is the survival benefit observed in patients with AMI in whom reperfusion was achieved after substantial myocardial salvage was no longer possible, ie, the time-independent effect of reestablishing an open IRA. In the prethrombolytic era, spontaneous reperfusion (which usually occurs many hours or even days after the onset of AMI) was found to be associated with improved left ventricular function. There is considerable evidence that non-Q-wave MI Thrombolytic therapy administered relatively late in the course of AMI also appears to improve survival. Data pooled from the early, small, randomized trials showed a 22% reduction in mortality among patients who received thrombolytic therapy 12 to 24 hours after the onset of symptoms9-long after the time when significant myocardial salvage could be expected. The ISIS-2 trial also included patients who presented relatively late in the course of their AMI. Subgroup analysis showed that the odds of vascular death at 5 weeks was reduced by 20% in those given SK and aspirin 13 to 24 MUI | hours after the onset of symptoms.13 A meta-analysis also revealed a significant improvement in survival among patients treated with thrombolytic agents 6 to 24 hours after symptom onset.," In all instances, however, benefit was greater with earlier treatment.
The LATE trial specifically addressed the use of thrombolytic therapy in patients who presented 6 to 24 hours after the onset of symptoms of AMP45; 5711 patients were randomized to either t-PA or placebo. At 35 days, there was a 26% reduction in mortality in the t-PA-treated patients who presented 6 to 12 hours after the onset of symptoms; however, patients who received thrombolytic therapy 13 to 24 hours after the event derived no benefit in terms of survival. In the EMERAS trial, in-hospital mortalities were nearly identical among 3600 patients with AMI who presented between 6 and 24 hours after the onset of symptoms and were randomized to SK or placebo (11.9% versus 12.4%, respectively [P=NS]). 46 Although not statistically significant, there was a 14% reduction in mortality in patients treated with the thrombolytic agent between 6 and 12 hours.
Evidence is therefore accumulating that, like the effects of late occurrence of spontaneous recanalization of the IRA, thrombolytic therapy given more than 6 hours after the onset of symptoms may improve ventricular function and survival even though little if any salvage of myocardium occurs beyond that time. When thrombolytic agents have been administered > 12 hours after the onset of symptoms, the results have been ambiguous, perhaps because these drugs are relatively ineffective in establishing coronary patency when clots are long-standing. However, late reperfusion, whether achieved spontaneously (see above) or by means of angioplasty (see below), appears to improve clinical outcome.
The "Open-Artery Hypothesis"
The concept that a patent IRA and myocardial reperfusion confer a benefit above and beyond that resulting from myocardial salvage has given rise to what has been called the "open-artery hypothesis," for which there is now considerable support.27 '47 patients with single-vessel coronary artery disease who experienced a first Q-wave MI, patency of the IRA was found to be an independent predictor of survival on multiple logistic regression analysis.50 In the SAVE Trial, post-MI patency of the IRA was also identified as an independent predictor of a lower incidence of a combined clinical end point (cardiovascular death, severe heart failure, recurrent infarction, or marked deterioration of LVEF). At an average follow-up of 3.5 years, 36% of the patients with a patent IRA had reached one of these clinical end points, compared with 51% in those with an occluded IRA. 51 Trials of thrombolysis have also shown that IRA patency correlates strongly with improved survival, both short-term and long-term (Fig 3) .52 For 108 Vatterott et al109 found that in post-AMI patients, a closed IRA was the most powerful independent predictor of late potentials and that they occurred in a lower fraction of patients given thrombolytic therapy. Lange et al1l0 also reported late potentials in 8% and 40% of patients with open and closed IRAs, respectively. The presence of late potentials in patients receiving thrombolytic agents appears to correlate with persistent occlusion of the IRA. 109, [111] [112] [113] Conversely, the absence of late potentials was associated with persistently viable, presumably hibernating myocardium in patients in whom patency of the IRA had been achieved by angioplasty an average of 12 days after AMI."4."5 In a substudy of the LATE trial, 45 Steinberg et al1"6 found that t-PA treatment 6 to 12 hours after the onset of symptoms resulted in a small but significantly shorter total QRS duration (the most powerful signal-averaged ECG predictor of adverse events) than did placebo treatment.
Implications for the Future The enormous benefits of establishing patency of the IRA within 1 or 2 hours of coronary occlusion result primarily from myocardial salvage. Vigorous efforts to achieve reperfusion as early as possible after the development of severe myocardial ischemia must be continued and indeed intensified."15 In addition, reocclusion after successful reperfusion is associated with a poor outcome, so efforts must be made to maintain patency once the IRA is opened by thrombolytic therapy. New adjunctive drugs such as novel new antiplatelet agents and specific antithrombins such as hirudin,"7 designed to prevent reocclusion, are being actively investigated. The substantial benefits of myocardial reperfusion-ie, prevention of infarct expansion, reduction of ventricular remodeling, and improvement of electrical stability-all appear to accrue when IRA patency occurs >6 hours and perhaps even days after the onset of AMI. Therefore, attempts should be made to restore vessel patency in AMI beyond the traditional 6-hour "window" after the onset of symptoms. Thrombolytic therapy might be appropriate for up to 12 hours, whereas at a later time when thrombolytic agents are no longer as effective, primary mechanical revascularization, generally by means of angioplasty, may be more appropriate.
The Imaging with 9'9Tc-labeled sestamibi may also allow the success of thrombolytic therapy to be assessed noninvasively. Sestamibi rapidly accumulates in viable myocardial cells proportional to their perfusion; however, unlike thallium, it does not redistribute significantly as a function of time. Therefore, sestamibi has been used to define myocardium at risk during the early (pretreatment) phase of AMI and subsequently to determine myocardial perfusion and salvage after thrombolytic therapy.127- '29 It is hoped that the use of such noninvasive markers of vessel patency (perhaps in combination) as well as others now being developed will identify those patients with AMI who do not respond to thrombolytic therapy initially or in whom reocclusion has subsequently occurred. In such cases, angioplasty or retreatment can be considered to restore coronary patency.
As the open-artery hypothesis continues to be examined, it is clear that the original paradigm on which reperfusion in AMI was based must be expanded. Although substantial evidence suggests that it is beneficial to achieve (and maintain) late patency of the IRA, such evidence is still not strong enough to warrant radical changes in the care of patients with AMI. These changes would be expensive and resource intensive, involving the frequent use of rescue angioplasty for selected patients suspected of having failed thrombolytic therapy, as well as coronary arteriography before hospital discharge for all AMI patients who have received treatment with a thrombolytic followed by mechanical revascularization in patients with occluded vessels. This strategy would not be without risk, since coronary angioplasty in this setting could damage the non-infarct-related artery and lead to a reduction of collateral flow. However, in view of the importance and magnitude of the problem of management of patients with AMI and occluded coronary arteries, it is now appropriate to initiate a prospective, randomized trial to determine whether establishing late patency of the IRA will affect clinical outcome in such patients.
